Mountain Valley MD Announces Publication of Soluvec Trial Data in Therapeutic Delivery

Mountain Valley MD Holdings Inc. (the “Company” or “MVMD”) (CSE: MVMD) (OTCQB: MVMDF) (FRA: 20MP), a leading-edge publicly traded biotech company whose science includes that of novel solubilization methods for therapeutic compounds, is pleased to announce the recent peer-reviewed publication of the Company’s Soluvec study data in the journal, Therapeutic Delivery. The published study highlights the benefits of the Company’s patented Soluvec formulation, a novel, solvent-free aqueous Ivermectin invention. This proprietary Soluvec formulation was developed using the Company’s patented Quicksol solubilization technology, which aims to address the poor solubility challenges associated with Ivermectin and potentially other macrocyclic lactones.

The study confirmed that parenteral administration of Soluvec led to an Ivermectin drug exposure approximately seven times higher than traditional oral drug dosing, with greater bioavailability, offering potential for enhanced therapeutic effectiveness.

Key Findings from the Study:

• Improved Solubility with Soluvec: In the resolubilized product, Soluvec, Ivermectin was present as a mix of 28.0 nm particles and polysorbate-solubilized free Ivermectin. The total concentration was approximately 2,500 times greater than that of free Ivermectin in water.
• IVM Exposure Seven Times Higher: In beagle dogs treated parenterally with Soluvec (subcutaneous or intramuscular dosing), total exposure of Ivermectin was ∼seven-times higher than in dogs receiving a non-solubilized Ivermectin tablet of the same dose orally.
• Increased Duration of Exposure: Peak levels were higher and, most importantly for ease of treatment, duration of exposure was reliably greater with parenteral dosing; all Soluvec-treated animals had detectable IVM at 48 h, versus none of the non-solublized Ivermectin orally dosed animals.
• Lower Doses Possible: Enhanced bioavailability of IVM in Soluvec suggests that a lower dose may achieve the desired therapeutic effects, potentially leading to reduced treatment costs and fewer side effects.
• Safety Profile: Research underscores favourable safety profile of Soluvec, with minimal side effects generally observed in test subjects.
• Potential Human and Livestock Applications: The results point to the possibility of easier treatment regimens and improved therapeutic outcomes not just for livestock but potentially for humans as well.

“MVMD deems this research as particularly significant given our belief, and what is common knowledge among scientists, that the poor solubility of the avermectin drug class (a series of drugs and pesticides used to treat parasitic worms and insect pests) remains a barrier to achieving and maintaining therapeutic drug levels in humans and livestock species,” stated Dennis Hancock, President & CEO of Mountain Valley MD. “As outlined in the publication, it is likely this challenge will continue for the coming decade and may worsen with stronger drug resistance becoming the reality. Conventional Ivermectin formulations simply have not been able to achieve and maintain therapeutic drug levels, compromising the effectiveness of treatments.”